MedTrace Logo

Study of Dextromethorphan in OCD and Related Disorders

NCT04899687 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-20

No results posted yet for this study

Summary

The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.

Conditions

  • Obsessive-Compulsive Disorder
  • Illness Anxiety Disorder
  • Body Dysmorphic Disorders
  • Somatic Symptom Disorder

Interventions

DRUG

Fluoxetine

Fluoxetine 20mg (or previously prescribed dose) will be taken once daily by mouth for 8 weeks

DRUG

Dextromethorphan

Dextromethorphan, an over-the-counter cough suppressant, will be taken by mouth twice daily for four weeks of the study, starting at 15mg per dose, and increasing weekly as tolerated to a maximum of 60mg per dose.

Sponsors & Collaborators

Principal Investigators

  • Peter J van Roessel, MD PhD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-20
Primary Completion
2027-04-01
Completion
2028-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04899687 on ClinicalTrials.gov